Engage-COVID-19: A mixed methods study of biomedical, behavioural, and psychosocial aspects of the COVID-19 pandemic among gay, bisexual, and other men who have sex with men in Canada [Added supplement: COVID-19 Variant Supplement]
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:0 publications
Grant number: 172677, 175548
Grant search
Key facts
Disease
COVID-19Start & end year
20202022Known Financial Commitments (USD)
$545,795.14Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
John Joseph Cox, Daniel Grace, Trevor Adam Hart, Jody Jollimore, Nathan John Lachowsky, Gilles Lambert, David M Moore…Research Location
CanadaLead Research Institution
University of TorontoResearch Priority Alignment
N/A
Research Category
Policies for public health, disease control & community resilience
Research Subcategory
Approaches to public health interventions
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Adults (18 and older)
Vulnerable Population
Sexual and gender minorities
Occupations of Interest
Unspecified
Abstract
Gay, bisexual, and other men who have sex with men (GBM) have historically experienced significant disparities in physical, mental, and sexual health, amplified by systemic marginalization and high barriers to healthcare. This context of inequity creates heightened vulnerabilities to COVID-19. Failure to respond to the health and wellness needs of GBM may have significant negative effects on COVID-19 outcomes and exacerbate existing health disparities. We propose the Engage-COVID-19 Study to rapidly respond to current and pressing knowledge gaps concerning the COVID-19 pandemic among GBM in Canada. This study will be embedded within the Engage Cohort Study, which is the only study with comparable biobehavioural data on HIV/STI prevalence and risk behaviours for GBM in Canada. To date, baseline data collection has been completed with 1842 GBM who are enrolled in the Engage Cohort Study (565 in Vancouver, 388 in Toronto, and 889 in Montreal). All of these participants will be invited to have SARS-CoV-2 antibody testing and complete an in-depth survey that will include COVID-specific quantitative questions. We anticipate recruiting a total sample of 1695-1768 participants. In addition, from this group we will recruit 90 GBM participants for qualitative interviews in Vancouver (30), Toronto (30), and Montreal (30) to assess the direct and indirect impacts of COVID-19 on Canadian GBM. These data are necessary both to understand COVID-19 risks, vulnerabilities, and prevention strategies, as well as the impacts of COVID-19 on health service access and different levels of HIV/STI risk across provinces. By making efficient use of available research infrastructure, our proposed study will ascertain the occurrence of COVID-19 by documenting SARS-CoV-2 immunity within both HIV-positive and -negative participants and produce rapid, high-quality evidence for preventing the direct and indirect effects of COVID-19 for this population across multiple jurisdictions.